Acumen Pharmaceuticals IncNASDAQ:ABOS
- LAST PRICE3.7200
- TODAY'S CHANGE (%)0.3600 (10.7143%)
- Bid / Lots3.7100/ 3
- Ask / Lots3.7200/ 3
- Open / Previous Close3.5900 / 3.3600
- Day Range
- 52 Week Range
- Volume109,866
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABOS |
|---|---|---|
| 09:32 ET | 5655 | 3.53 |
| 09:34 ET | 1449 | 3.605 |
| 09:36 ET | 700 | 3.58 |
| 09:38 ET | 1725 | 3.55 |
| 09:39 ET | 875 | 3.58 |
| 09:41 ET | 825 | 3.57 |
| 09:43 ET | 1300 | 3.58 |
| 09:45 ET | 324 | 3.58 |
| 09:48 ET | 233 | 3.59 |
| 09:50 ET | 400 | 3.59 |
| 09:52 ET | 200 | 3.605 |
| 09:56 ET | 229 | 3.61 |
| 09:57 ET | 1500 | 3.6052 |
| 09:59 ET | 293 | 3.6 |
| 10:03 ET | 200 | 3.58 |
| 10:08 ET | 443 | 3.5604 |
| 10:10 ET | 215 | 3.57 |
| 10:12 ET | 507 | 3.56 |
| 10:14 ET | 100 | 3.57 |
| 10:17 ET | 438 | 3.54 |
| 10:19 ET | 200 | 3.53 |
| 10:24 ET | 1000 | 3.51 |
| 10:28 ET | 1050 | 3.52 |
| 10:32 ET | 2472 | 3.52 |
| 10:33 ET | 300 | 3.51 |
| 10:39 ET | 200 | 3.5 |
| 10:44 ET | 100 | 3.5 |
| 10:46 ET | 100 | 3.51 |
| 10:51 ET | 200 | 3.505 |
| 10:53 ET | 904 | 3.54 |
| 10:55 ET | 100 | 3.54 |
| 11:04 ET | 776 | 3.56 |
| 11:06 ET | 200 | 3.555 |
| 11:09 ET | 100 | 3.56 |
| 11:13 ET | 100 | 3.56 |
| 11:18 ET | 200 | 3.5599 |
| 11:20 ET | 100 | 3.56 |
| 11:22 ET | 200 | 3.57 |
| 11:26 ET | 300 | 3.565 |
| 11:31 ET | 325 | 3.56 |
| 11:40 ET | 100 | 3.56 |
| 11:44 ET | 400 | 3.55 |
| 11:45 ET | 737 | 3.56 |
| 11:49 ET | 772 | 3.58 |
| 11:51 ET | 100 | 3.59 |
| 11:58 ET | 500 | 3.59 |
| 12:03 ET | 6910 | 3.61 |
| 12:05 ET | 100 | 3.62 |
| 12:09 ET | 289 | 3.612 |
| 12:16 ET | 300 | 3.605 |
| 12:18 ET | 126 | 3.605 |
| 12:23 ET | 627 | 3.6 |
| 12:25 ET | 3175 | 3.645 |
| 12:27 ET | 7226 | 3.6955 |
| 12:30 ET | 2328 | 3.6955 |
| 12:34 ET | 1000 | 3.69 |
| 12:38 ET | 1518 | 3.67 |
| 12:41 ET | 126 | 3.675 |
| 12:43 ET | 844 | 3.69 |
| 12:45 ET | 1408 | 3.7 |
| 12:48 ET | 9801 | 3.68 |
| 12:50 ET | 100 | 3.685 |
| 12:54 ET | 3717 | 3.675 |
| 12:59 ET | 608 | 3.675 |
| 01:01 ET | 100 | 3.6711 |
| 01:03 ET | 845 | 3.68 |
| 01:06 ET | 1658 | 3.7 |
| 01:08 ET | 1000 | 3.705 |
| 01:10 ET | 5268 | 3.7229 |
| 01:14 ET | 500 | 3.72 |
| 01:15 ET | 700 | 3.72 |
Today
Press Release: Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesAcumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights, from 6 hours ago by Dow Jones
6 hours ago by Dow Jones
Yesterday
May 8, 2024
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference, from 5:47PM ET on Wednesday May 08, 2024 by Dow Jones
5:47PM ET on Wednesday May 08, 2024 by Dow JonesAcumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease, from 8:00AM ET on Wednesday May 08, 2024 by Dow Jones
8:00AM ET on Wednesday May 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acumen Pharmaceuticals Inc | 201.9M | -3.4x | --- |
Kodiak Sciences Inc | 201.2M | -0.8x | --- |
INmune Bio Inc | 196.2M | -6.1x | --- |
Prelude Therapeutics Inc | 208.7M | -2.1x | --- |
Zura Bio Ltd | 208.8M | -1.2x | --- |
Elevation Oncology Inc | 193.4M | -3.5x | --- |
Company Information
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.
Contact Information
- Headquarters
- 427 PARK ST.CHARLOTTESVILLE, VA, United States 22902
- Phone
- 925-368-8508
- Fax
- 302-636-5454
Executives
- President, Chief Development Officer
- James Doherty
- Chief Executive Officer, Director
- Daniel O'Connell
- Co-Founder, Chief Scientific Advisor
- Grant Krafft
- Chief Financial Officer, Chief Business Officer
- W. Matthew Zuga
- Chief Operating Officer
- Russell Barton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $201.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 60.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.08 |
Book Value | $4.61 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
